DTaP-poliovirus vaccine adult - GlaxoSmithKline

Drug Profile

DTaP-poliovirus vaccine adult - GlaxoSmithKline

Alternative Names: Boostrix Polio; Boostrix-IPV

Latest Information Update: 27 Mar 2012

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 10 Feb 2012 GlaxoSmithKline completes enrolment in its phase IV trial in France and Germany (NCT01323959)
  • 06 Jan 2006 Registered for Diphtheria in India (IM)
  • 06 Jan 2006 Registered for Pertussis in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top